Arctic Bioscience - Notice of Annual General Meeting on 21 April 2023

14 Apr 2023 10:00 CEST

Arctic Bioscience AS' Annual General Meeting will be held Friday 21 April 2023
at 14:00 (CET), as a digital meeting.

Shareholders are encouraged to cast their votes in advance of the General
Meeting or grant the Chair of the Board a proxy, with or without voting
instructions.

Deadline for registration of attendance, advance votes, proxy or instructions is
20 April 2023 at 14:00 (CET). For attendance to the live event, please follow
the instruction in the notice.

For further information, see the attached Notice of the Annual General Meeting,
which can also be accessed from the company's website (https://arctic
-bioscience.com/investors/general-meetings/).

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

For more information, please contact:

Christer L. Valderhaug

CEO

Phone: +47 920 84 601

E-mail: christer@arctic-bioscience.com

Jone R. Slinning

CFO

Mobile: +47 948 75 469

E-mail: jone@arctic-bioscience.com

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing
pharmaceutical and nutraceutical products based on unique bioactive marine
compounds.

The company is developing HRO350 - a novel investigational drug candidate.
HRO350 is being developed for treatment of patients with mild-to-moderate
psoriasis. This is a large patient group in need of new effective medicines with
beneficial safety profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as
well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a team of highly competent people with experience in
developing marine oils and experience from global pharmaceutical companies.

More information:
Access the news on Oslo Bors NewsWeb site

587630_20230414_ABS_Notice_AGM_2023.pdf